Please Wait
Applying Filters...
menu
    • menu
    Evonik

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

    Virtual Booth

    Contact Supplier

    Temad- We think of world-class quality.

    Virtual Booth

    Contact Supplier

    Menu

    Lonafarnib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 19,836Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Er-Kim, Sentynl Therapeutics Partner On Nulibry & Zokinvy
    Er-Kim, Sentynl Therapeutics Partner On Nulibry & Zokinvy

    24 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/24/3155462/0/en/Er-Kim-Enters-Commercialization-Agreement-with-Sentynl-Therapeutics-for-Nulibry-fosdenopterin-and-Zokinvy-lonafarnib-Targeting-Ultra-Rare-Diseases.html

    GLOBENEWSWIRE
    24 Sep 2025
    Share Share
    Sentynl Acquires Zokinvy® For Progeria From Eiger Globally
    Sentynl Acquires Zokinvy® For Progeria From Eiger Globally

    03 May 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/sentynl-therapeutics-announces-global-acquisition-of-zokinvy-lonafarnib-for-treatment-of-hutchinson-gilford-progeria-syndrome-from-eiger-biopharmaceuticals-302135968.html

    PR NEWSWIRE
    03 May 2024
    Share Share
    Eiger Files for Bankruptcy, Plans to Shutter Operations After Difficult Year
    Eiger Files for Bankruptcy, Plans to Shutter Operations After Difficult Year

    02 Apr 2024

    // BIOSPACE

    https://www.biospace.com/article/eiger-files-for-bankruptcy-plans-to-shutter-operations-after-difficult-year/

    BIOSPACE
    02 Apr 2024
    Share Share
    Eiger BioPharmaceuticals Files for Voluntary Chapter 11 Protection
    Eiger BioPharmaceuticals Files for Voluntary Chapter 11 Protection

    01 Apr 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/04/01/2855277/0/en/Eiger-BioPharmaceuticals-Files-for-Voluntary-Chapter-11-Protection.html

    GLOBENEWSWIRE
    01 Apr 2024
    Share Share
    Eiger and Partner, AnGes, Receive Approval for Zokinvy) for Hutchinson
    Eiger and Partner, AnGes, Receive Approval for Zokinvy) for Hutchinson

    18 Jan 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/eiger-and-partner-anges-receive-approval-for-zokinvy-lonafarnib-for-hutchinson--gilford-progeria-syndrome-and-processing-deficient-progeroid-laminopathies-in-japan-302038919.html

    PR NEWSWIRE
    18 Jan 2024
    Share Share
    EigerBio's Zokinvy (lonafarnib) Receives Approval in Europe
    EigerBio's Zokinvy (lonafarnib) Receives Approval in Europe

    24 Mar 2023

    // EMA

    https://www.ema.europa.eu/en/documents/overview/zokinvy-epar-medicine-overview_en.pdf

    EMA
    24 Mar 2023
    Share Share